Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs , a randomized, open‐label study-Reference-Cited by-同舟云学术

Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs , a randomized, open‐label study

Published:2021-11-17 Issue:1 Volume:76 Page:22-31
ISSN:1323-1316
Container-title:Psychiatry and Clinical Neurosciences
language:en
Short-container-title:Psychiatry Clin Neurosci

Author:

Ishigooka Jun¹^ORCID,Nakagome Kazuyuki²,Ohmori Tetsuro³,Iwata Nakao⁴,Inada Ken¹^ORCID,Iga Jun‐ichi²^ORCID,Kishi Taro⁴^ORCID,Fujita Kiyoshi⁵,Kikuchi Yuka⁶,Shichijo Toshiaki⁷,Tabuse Hideaki⁸,Koretsune Shotatsu⁹,Terada Hiroshi¹⁰,Terada Haruko¹⁰,Kishimoto Toshifumi¹¹,Tsutsumi Yuichiro¹²,Kanda Yoshiki¹³,Ohi Kazutaka¹⁴^ORCID,Sekiyama Kanji¹⁵

Affiliation:

1. Department of Psychiatry Tokyo Women's Medical University, School of Medicine Tokyo Japan

2. Department of Psychiatry National Center of Neurology and Psychiatry Tokyo Japan

3. Department of Psychiatry Tokushima University Graduate School of Biomedical Sciences Tokushima Japan

4. Department of Psychiatry Fujita Health University School of Medicine Toyoake‐shi Japan

5. Okehazama Hospital Fujita Kokoro Care Center Toyoake‐shi Japan

6. Department of Psychiatry Akita University Hospital Akita Japan

7. Mental Clinic Minami Saitama Japan

8. Department of Psychiatry Holy Cross Hospital Toki‐shi Japan

9. Kokoro no clinic Narimasu Tokyo Japan

10. Aoi Clinic Shizuoka Japan

11. Department of Psychiatry Nara Medical University Kashihara‐shi Japan

12. Department of Psychiatry Ongata Hospital Hachioji‐shi Japan

13. Musashikoganei Minamiguchi Shinryou Clinic Koganei‐shi Japan

14. Department of Neuropsychiatry Kokubu Hospital Osaka Japan

15. Sekiyama Psychiatric Clinic Tokyo Japan

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical),Neurology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pcn.13304

Reference46 articles.

1. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016

2. The Ministry of Health Labour and Welfare.Statistics by Ministry of Health Labour and Welfare as of 2008. [Cited 3 November 2020] Available from URL:http://www.mhlw.go.jp/kokoro/speciality/detail_into.html.

3. National Institute for Health and Care Excellence.NICE guideline 2014. Psychosis and schizophrenia in adults: prevention and management. [Cited 3 November 2020] Available from URL:https://www.nice.org.uk/guidance/cg178/chapter/1‐Recommendations#promoting‐recovery‐and‐possible‐future‐care‐2.

4. American Psychiatric Association. APA practical guideline2019. [Cited 3 November 2020] Available from URL:https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.177901.https://www.psychiatry.org/psychiatrists/practice/clinical‐practice‐guidelines

5. The Japanese Society of Neuropsychopharmacology.“Guideline for Pharmacological Therapy of Schizophrenia” [Cited 3 November 2020] Available from URL:http://www.asas.or.jp/jsnp/csrinfo/03.html.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical effectiveness of paliperidone palmitate 3‐monthly and 1‐monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database;Neuropsychopharmacology Reports;2024-09-11

2. Randomized open-label study of second-generation antipsychotics for the treatment of schizophrenia: 104-week final results of the JUMPs study assessing treatment discontinuation, remission, and social functioning;BMC Psychiatry;2024-09-05

3. Investigating Cannabidiol's potential as a supplementary treatment for schizophrenia: A narrative review;European Journal of Pharmacology;2024-09

4. Real-World Effectiveness, Economic, and Humanistic Outcomes of Selected Oral Antipsychotics in Patients with Schizophrenia: A Systematic Review Evaluating Global Evidence;ClinicoEconomics and Outcomes Research;2024-09

5. A multicenter, single‐arm, open‐label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder;Neuropsychopharmacology Reports;2024-01-22